GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (NAS:AMRX) » Definitions » Effective Interest Rate on Debt %

Amneal Pharmaceuticals (Amneal Pharmaceuticals) Effective Interest Rate on Debt % : 8.58% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Amneal Pharmaceuticals Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Amneal Pharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $238 Mil. Amneal Pharmaceuticals's average total debt for the quarter that ended in Dec. 2023 was $2,778 Mil. Therefore, Amneal Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 8.58%.


Amneal Pharmaceuticals Effective Interest Rate on Debt % Historical Data

The historical data trend for Amneal Pharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amneal Pharmaceuticals Effective Interest Rate on Debt % Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial 6.16 5.11 4.68 5.54 7.53

Amneal Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.60 6.92 7.12 7.19 8.58

Competitive Comparison of Amneal Pharmaceuticals's Effective Interest Rate on Debt %

For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amneal Pharmaceuticals's Effective Interest Rate on Debt % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Amneal Pharmaceuticals's Effective Interest Rate on Debt % falls into.



Amneal Pharmaceuticals Effective Interest Rate on Debt % Calculation

Amneal Pharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -210.629/( (2845.135+2750.523)/ 2 )
=-1  *  -210.629/2797.829
=7.53 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2740.496 + 104.639
=2845.135

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2522.899 + 227.624
=2750.523

Amneal Pharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  -238.192/( (2804.688+2750.523)/ 2 )
=-1  *  -238.192/2777.6055
=8.58 %

where

Total Debt  (Q: Sep. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2682.176 + 122.512
=2804.688

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2522.899 + 227.624
=2750.523

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Amneal Pharmaceuticals  (NAS:AMRX) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Amneal Pharmaceuticals Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Amneal Pharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amneal Pharmaceuticals (Amneal Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies.
Executives
Andrew S Boyer officer: Exec VP, Comm Optns C/O WATSON PHARMA INC, 360 MOUNT KEMBLE AVE, MORRISTOWN NJ 07960
Tpg Gp A, Llc 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Gustavo Pesquin officer: See Remarks 4 PARK LANE, MADISON NJ 07940
Deborah M. Autor director C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Jason B. Daly officer: SVP, Chief Legal Officer 400 CROSSING BLVD, 3RD FLOOR, BRIDGEWATER NJ 08807
Jon Winkelried 10 percent owner C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Gautam Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Chirag K. Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Chintu Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER CA 08807
Nikita Shah officer: SVP, Chief HR Officer C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Joseph Todisco officer: SVP, Specialty Commercial 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
John Kiely director C/O ZOVIO INC, 1811 E NORTHROP BLVD, CHANDLER AZ 85286
Jeffrey P. George director C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Shlomo Yanai director ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Paul M Meister director 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862